

American Association for the Study of Liver Diseases (AASLD)

and

Infectious Diseases Society of America (IDSA)

Recommendations for Testing, Managing
and Treating Hepatitis C

Released January 29, 2014

**Patients who are Treatment-Naïve or
Patients who Relapsed* after a Course of PEG+RIBA Therapy**

Read the table from left to right, one row is one full treatment course.

*relapse = virus is undetectable after treatment, but is detectable after 6 months

**PEG = pegylated interferon (several branded products available)

***RIBA = ribavirin (generic)

Viral Genotype	PEG**	RIBA***	Boceprevir (2011, Victrelis®)	Simeprevir (2014, Olysio®)	Sofosbuvir (2014, Sovaldi®)	Telaprevir (2011, Incivek®)
1 (any subtype)	12 weeks	12 weeks			12 weeks	
1b or 1a without Q80K	24 weeks	24 weeks		12 weeks		
1 (any subtype)		<u>Optional</u> 12 weeks		12 weeks	12 weeks	
1 (any subtype)		24 weeks			24 weeks	
2		12 weeks			12 weeks	
3		24 weeks			24 weeks	
3	12 weeks	12 weeks			12 weeks	
4	12 weeks	12 weeks			12 weeks	
4	24 to 48 weeks	24 to 48 weeks		12 weeks		
4		24 weeks			24 weeks	
5 or 6	12 weeks	12 weeks			12 weeks	
5 or 6	48 weeks	48 weeks				

Patients who Failed**** a Course of PEG+RIBA Therapy

****Failure = Non-Response = Hepatitis C virus is detectable and/or liver function tests are abnormal as therapy progresses

Viral Genotype	PEG**	RIBA***	Boceprevir (2011, Victrelis®)	Simeprevir (2014, Olysio®)	Sofosbuvir (2014, Sovaldi®)	Telaprevir (2011, Incivek®)
1		Optional 12 weeks		12 weeks	12 weeks	
1	12 weeks	12 weeks			12 weeks	
1	24 weeks	24 weeks		12 weeks		
2		12 weeks			12 weeks	
2	12 weeks	12 weeks			12 weeks	
3		24 weeks			24 weeks	
3	12 weeks	12 weeks			12 weeks	
4	12 weeks	12 weeks			12 weeks	
4		24 weeks			24 weeks	
4	24 to 48 weeks	24 to 48 weeks		12 weeks		
5 or 6	12 weeks	12 weeks			12 weeks	
5 or 6		24 weeks			24 weeks	

Note that not all treatments require PEG.

Note that boceprevir and telaprevir are never recommended.